Xu is passionate about understanding information and knowledge related to biopharma industry. She is bilingual in Mandarin and English. Prior to this, Xu worked as a medical writer and wrote publications based on data from clinical trials for a wide range of therapeutic areas for global pharmaceutical companies. She holds a Master degree in Medical Pharmaceutical Science from University of Groningen and a PhD degree in Biomedical Science from Vrije Universiteit Amsterdam in the Netherlands.
Latest from Xu Hu
Among products granted conditional approval in China over the 2020-22 period, the completion of confirmatory trials and conversion to traditional approval took up to a median of five years, according to a Pink Sheet analysis.
Plus deals involving Adagene/Third Arc, Celltrion/TRiOar, Celltrion/Kaigene, ImmunoScape/Cue, Laekna/Qilu, Lilly/ABL, Lilly/Sanegene, Sanyou/ZJ Bio-Tech, TransThera/Neurocrine, Qyuns/Roche, Otsuka/4D Molecular, IASO/GC Cell, Chugai/Renalys, Henlius/Forlong and Teijin/Elevara.
Ascletis’ peptide co-formulation of ASC36 and ASC35 outperformed the co-formulation of Eli Lilly’s eloralintide and tirzepatide as well as eloralintide alone in a rat model, boosting the China-based firm’s confidence in upcoming clinical outcomes.
China’s NHSA expects to release the first list of innovative drugs to be covered by commercial health insurance in early December, but implementation, payment collection and data sharing are expected to be among the main hurdles ahead.
Boehringer’s PDE4B inhibitor Jascayd was approved for IPF in China on Oct. 22, marking its second nod globally soon after the US. The German firm discusses with Scrip the opportunities and challenges in this market.
RemeGen’s disitamab vedotin in combination with toripalimab significantly improved OS/PFS in Chinese patients with HER2-positive advanced urothelial carcinoma regardless of HER2 expression levels, meaning over 80% of patients with this condition could potentially benefit.